Prelude Therapeutics share price logo

Prelude Therapeutics

NASDAQ: PRLD

Small Cap

$5.25

-0.18

(-3.31%)

as on

Prelude Therapeutics Stock Performance

as on September 4, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $5.11
    $5.45
    downward going graph

    2.67%

    Downside

    3.81%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.98
    $6.83
    downward going graph

    81.32%

    Downside

    30.10%

    Upside

    downward going graph

Prelude Therapeutics share price movements today

Previous Close
$5.43
Open
$5.45
Volume
866.3K
Market Cap
$433.3M
Day's Low - High
$5.11 - $5.45
52 Week Low - High
$0.98 - $6.83

Prelude Therapeutics Historical Returns

1 Month Return
+ 16.15 %
3 Month Return
+ 28.68 %
1 Year Return
+ 360.53 %
3 Year Return
+ 43.44 %
5 Year Return
-85.96 %

Prelude Therapeutics Stock Fundamentals & Key Indicators

Check Prelude Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$433.3M

EPS (TTM)

-0.54

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-64.5M

Revenue (TTM)

22.4M

Profit Margin

-269.75%

Return On Equity TTM

-57.73%

Prelude Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Prelude Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
SELL$433.3M-85.96%NA-269.75%NA
BUY$44.6B614.61%NA0.00%NA
BUY$141.1B181.73%32.2186.04%NA
BUY$60.2B-64.27%-18.66-12.57%NA
BUY$84.8B24.12%20.1484.86%0.44%

Stock Returns calculator for Prelude Therapeutics Stock including INR - Dollar returns

The Prelude Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Prelude Therapeutics investment value today

Current value as on today

₹4,93,382

Returns

₹3,93,382

(+393.38%)

Returns from Prelude Therapeutics Stock

₹3,60,526 (+360.53%)

Dollar Impact

₹32,856 (+32.86%)

Analyst Recommendation on Prelude Therapeutics Stock

Based on 1 analysts

SELL

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 1 analysts, 100% of analysts recommend a 'SELL' rating for Prelude Therapeutics. Average target price of $8

Prelude Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Prelude Therapeutics.

What analysts predicted

34.38%UPSIDE

Target Price

$8

Current Price

$5.25

Analyzed by

1 Analysts

Target

$8.00

Prelude Therapeutics target price $8, a slight upside of 34.38% compared to current price of $5.25. According to 1 analysts rating.

Indian Investors' Interest in Prelude Therapeutics Stock

Search interest for Prelude Therapeutics Stock has increased by 23% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:23% versus previous 30 day period

Prelude Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
3
4
-
-
6
5
4
5
Gross Profit
0
0
3
4
0
0
6
5
4
5
Operating Income
-34
-37
-34
-33
-34
-32
-20
-17
-14
-15
EBITDA
-31
-34
-31
-28
-31
-30
-19
-16
-9
-13
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-31
-34
-32
-28
-32
-31
-19
-16
-10
-13
Income Tax Expense
0
-
-
-
-
-
-
-
-
-
Net Income
-31
-34
-32
-28
-32
-31
-19
-16
-10
-13
Net Profit Margin
0.00%
0.00%
-1075.70%
-718.28%
0.00%
0.00%
-303.46%
-291.79%
-226.75%
-244.06%

Prelude Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
7
12
Gross Profit
0
0
0
-2
-3
-1
7
10
Operating Income
-14
-28
-58
-113
-123
-132
-139
-104
EBITDA
-14
-27
-58
-112
-122
-120
-125
-97
Interest Expense
-
-
-
2
1
-
-
-
Depreciation
0
0
0
0
1
1
1
1
Income Before Tax
-14
-27
-56
-111
-115
-121
-127
-99
Income Tax Expense
0
0
0
0
-8
0
-
-
Net Income
-14
-27
-56
-110
-107
-121
-127
-99
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
-1816.76%
-819.59%

Prelude Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-34
-32
-28
-32
-31
-19
-16
-10
-13
Operating Cash Flow
-23
-27
-20
-34
-26
-19
23
-21
-15
Investing Cash Flow
26
10
22
62
11
40
-60
8
-65
Financing Cash Flow
0
0
0
0
0
0
24
0
85
Change in Cash
3
-16
1
27
-14
20
-12
-13
4

Prelude Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-27
-56
-111
-115
-121
-127
-99
Operating Cash Flow
-25
-46
-83
-83
-107
-102
-56
Investing Cash Flow
0
0
-263
81
-34
90
53
Financing Cash Flow
29
246
164
0
136
0
24
Change in Cash
3
199
-182
-1
-5
-12
21

Mutual Funds that own Prelude Therapeutics Stock

Check out the Mutual Funds with significant holdings in Prelude Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
1.84272%
1199157
Fidelity Concord Street Trust
0.354473%
230675
Bridgeway Funds, Inc.
0.076834%
50000
VANGUARD INSTITUTIONAL INDEX FUNDS
0.028322%
18431
DFA INVESTMENT DIMENSIONS GROUP INC
0.026309%
17121

Global Institutional Holdings in Prelude Therapeutics

Funds
Holdings
Felix Baker
15.56%
Peter Kolchinsky
9.95%
Vanguard
3.32%
iShares
1.54%
Bridgeway
0.09%

Prelude Therapeutics News & Key Events

    Insights on Prelude Therapeutics

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 6 months, PRLD stock has moved up by 86.8%

    • imgPOSITIVE IMPACT

      Best in 3 Years

      img

      In the last 3 years, PRLD has outperformed top 5 stocks with highest market-cap in its industry

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Moderna, Inc. Common Stock has given 513.1% return, outperforming this stock by 152.6%

    About Prelude Therapeutics

    Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
    OrganisationPrelude Therapeutics
    Headquarters175 Innovation Boulevard, Wilmington, DE, United States, 19805
    IndustryBiotechnology
    CEODr. Krishna Vaddi D.V.M., Ph.D.
    E-voting on sharesClick here to vote

    Key Management of Prelude Therapeutics

    Name

    Title

    Dr. Krishna Vaddi D.V.M., Ph.D.

    Founder, CEO & Director

    Ms. Aimee Crombie Ph.D.

    Senior VP and Head of Strategic Planning & Operations

    Dr. Madhu Pudipeddi Ph.D.

    Senior Vice President of Technical Operations

    Ms. Michele Porreca M.B.A.

    Chief People Officer

    Dr. Andrew P. Combs Ph.D.

    Executive VP & Chief Chemistry Officer

    Mr. Bryant David Lim J.D.

    CFO, Chief Legal Officer & Corporate Secretary

    Dr. Peggy A. Scherle Ph.D.

    Chief Scientific Officer

    Mr. Robert A. Doody Jr.

    Senior Vice President of Investor Relations

    Mr. Naveen Babbar Ph.D.

    Senior Vice President of Translation Medicine

    Dr. Wan-Jen Hong M.D.

    Senior Vice President of Clinical Development

    FAQs

    What is Prelude Therapeutics share price today?

    Prelude Therapeutics share price today is $5.25 as on at the close of the market. Prelude Therapeutics share today touched a day high of $5.45 and a low of $5.11.

    What is the 52 week high and 52 week low for Prelude Therapeutics share?

    Prelude Therapeutics share touched a 52 week high of $6.83 on and a 52 week low of $0.98 on . Prelude Therapeutics stock price today i.e. is closed at $5.25,which is 23.13% down from its 52 week high and 435.33% up from its 52 week low.

    What is Prelude Therapeutics's market capitalisation today?

    Prelude Therapeutics market capitalisation is $0.00T as on .

    How to invest in Prelude Therapeutics Stock (PRLD) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Prelude Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Prelude Therapeutics Shares that will get you 0.2857 shares as per Prelude Therapeutics share price of $5.25 per share as on September 4, 2026 at 8:45 am IST.

    What is the minimum amount required to buy Prelude Therapeutics Stock (PRLD) from India?

    Indian investors can start investing in Prelude Therapeutics (PRLD) shares with as little as ₹94.485 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹944.85 in Prelude Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Prelude Therapeutics share’s latest price of $5.25 as on September 4, 2026 at 8:45 am IST, you will get 1.9048 shares of Prelude Therapeutics. Learn more about fractional shares .

    What are the returns that Prelude Therapeutics has given to Indian investors in the last 5 years?

    Prelude Therapeutics stock has given -85.96% share price returns and 29.94% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?